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Summary.-Cyclosporin A (CyA), a novelimmunosuppressive agent withapparently
selective inhibitoryeffects on Tlymphocytes and little myelotoxicity, was tested for its
effects on a variety of syngeneic animal tumours including sarcomas, carcinomas and
a T-cell lymphoma. Cy A, given orally orparenterally in repeated doses, had no effect
on the growth rates of any of the tumours tested, but a highly significant effect on
metastasis was seen in many cases. All the sarcomas examined in both rats and mice,
and also the lymphoma, showed a marked increase in their metastases, in some
cases even when administration of Cy A was delayed until after excision of the
"primary" tumour implants. In contrast no effect ofCy A on metastasis was observed
in animals bearing poorly immunogenic mammary or squamous-cell carcinomas.
The metastases developing in Cy A-treated animals, when transplanted into normal
syngeneic animals, showed no evidence of enhanced metastatic potential compared
with their"parent" tumours.
CYCLOSPORIN A (Cy A) is a fungal
metabolite the immunosuppressive pro-
perties of which have been described by
Borel et al. (1978) and include inhibition of
humoral immunity (assayed by plaque-
forming cell number and haemagglutina-
tion titre) and cell-mediated immunity
(assayed by skin-graft rejection, graft-vs-
host disease and experimental allergic
encephalitis). It was shown to be effective
after oral or parenteral administration,
and to inhibit both primary and secondary
immune responses. Its mode of action is
still imperfectly understood, but in con-
trast to other immunosuppressive or cyto-
static drugs it has little effect on haemo-
poietic tissues and seems preferentially to
inhibit T lymphocytes at an early stage of
mitogenic triggering (Borel et al., 1978).
Further advantages are that its effects
seem to be reversed fairly rapidly, at least
in some systems (Denham et al., 1980) and
do not seriously compromise immunity to
common pathogens.
Previous work from this laboratory had
shown that when animals were putatively
immunosuppressed by thymectomy,
whole-body X-irradiation or chronic
lymph depletion, the incidence of meta-
stases from immunogenic tumours was
greatly increased and approached that of
poorly immunogenic tumours (Eccles &
Alexander, 1974, 1975). Although these
effects could be reversed by reconstitution
of the animals with lymphoid cells before
tumour implantation (Eccles, 1978) the
possibility that surgical stress or radiation
damage had contributed to the increased
incidence of metastases could not be dis-
counted entirely. Subsequently, it was
shown that similar tumours grown in con-
genitally athymic "nude" rats also ex-
hibited enhanced metastasis over immune-
competent hosts (Eccles et al., 1979;
Eccles, 1980) although the athymic rats
were of mixed genetic background, and
not syngeneic with the Lister Hooded/
Cbi tumours under investigation. Cyclo-
sporin A offered the possibility ofstudying
the growth and metastasis ofawide varietyCY A AND METASTASIS
of rat and mouse tumours in strictly
syngeneic hosts, subjected to specific
immune suppression not requiring surgery,
the use of antibiotics or filterbox housing
as had all previous experimental systems
used. In addition, the rapidity with which
Cy A exerts its effects, from which animals
recover after cessation of treatment,
allowed a more detailed examination of
the results of suppression of host T-
dependent immune responses at various
stages of tumour growth and after pri-
mary-tumour excision.
MATERIALS AND METHODS
Rat tumours.-Highly inbred male Lister
Hooded/Cbi rats were used between 10 and 12
weeks of age. The tumours studied were in-
duced in this colony of animals, all (except
HSN) within the last 3- years. MC24 and
MC26 fibrosarcomas were induced by methyl-
cholanthrene, and HSN sarcoma by benzo(a)-
pyrene.
Mouse tumours.-Male, and/or female mice
of inbred strains C57BL/Cbi, DBA/2 and
CBA/Ca were used between 10 and 12 weeks
of age. The tumours studied were as follows:
FS6 and FS29; benzpyrene-induced fibro-
sarcomas syngeneic with male and femnale
C57BL/Cbi mice respectively.
DM1, DM2 and DM6; squamous-cell
carcinomas induced in C57BL/Cbi mice by
skin-painting with DMBA (dimethylbenz-
anthracene) in 1979.
MT1, MT3 and MT5; mammary adeno-
carcinomas arising in 1979 as a result of
natural transmission of Bittner factor (mam-
mary-tumour virus) in female CBA/Ca mice,
transplanted in syngeneic virus-free female
mice.
L5178YE; a methylcholanthrene-induced
T-cell lymphoma of female DBA/2 mice,
introduced into our Institute in 1961.
Tumours were only studied in their first 10
in vivo transplant generations, before fresh
stocks were obtained from liquid N2, and
unless specified otherwise they were grown
from mechanically prepared cell suspensions,
and not subjected to proteolytic enzymes or
in vitro culture.
Cyclosporin A (Cy A).-Cyclosporin A
(OL-27-400) was kindly supplied by Sandoz
Ltd, Basle, in two forms: as a powder, which
was suspended in tragacanth and adminis-
18
tered orally by intubation under light ether
anaesthesia, and as a solution in oil which was
given s.c. or i.m. Control animals received
either oral tragacanth or inoculations of olive
oil as appropriate. Thedosageschedulesvaried
and are given with the details of particular
experiments.
Tumour growth studies.-Tumour-cell sus-
pensions-0 05 ml (mouse) or 0 1 ml (rat)-
were inoculated s.c. into the right flanks of
groups of 8 or 10 syngeneic animals. Half of
each group received daily s.c. injections of
Cy A in the contralateral flanks, beginning on
the day before tumour inoculation and con-
tinuing to the end of the experiments; con-
trols received an equal volume of olive oil.
The doses used were 20 mg/kg for rats, and
80 mg/kg for mice. Measurements of 2 per-
pendicular tumour diameters were made on
alternate days and results expressed as the
mean tumour diameter of groups of 4-5
animals. The effect of Cy A on the growth
rates of mouse tumours FS6, MT1 and
L5178Y and rat tumours MC24 and HSN
was assessed.
Studies of spontaneous metastasis.-For
these studies, tumours were generally grown
i.m. from 0 05 ml or 0-1 ml of tumour-cell
suspensions and excised after 10-14 days of
growth by hind-limb amputation. Animals
were then observed for up to one year, those
showing symptoms of metastases were killed
and necropsied, and at the end of the experi-
ment, surviving animals were also killed and
examined carefully. Suitable individual meta-
stases were selected regularly for trans-
plantation into further syngeneic animals, to
determine whether their inherent metastatic
potential was greater than in the original
"primary" tumour.
(a) The effect of oral Cy A on the meta-
stasis of mouse tumours FS6 and F829 was
studied. Ten animals received daily doses of
200 mg/kg Cy A per os on Days 3-10 of
tumour growth; 10 were treated on Days 3-10
after tumour excision and a further 10 served
as controls.
(b) The effect of s.c. administration of
Cy A was studied using rat tumours MC24,
MC26 and HSN.TC and mouse tumours DM1,
DM2, DM6, MT1, MT3 and MT5 and
L5178YE. HSN.TC refers to HSN sarcoma,
freed of host cells by 3 subcultures in vitro;
L5178YE was obtained by teasing apart
spleens of tumour-bearing mice. Both these
tumours were grown i.m. from 106 viable
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cells, and L5178YE was also grown s.c. Other
tumours were grown from mechanically pre-
pared cell suspensions. Groups of 10 mice
received daily doses of 80 mg/kg Cy A in oil
on Days 3-10 of tumour growth, the same
number of controls receiving an equivalent
volume (0-02 ml) of olive oil. Groups of 8 rats
-which seem to be more sensitive to Cy A-
received daily doses of 20 mg/kg on Days
3-10 of tumour growth or on Days 3-10 after
excision, whilst further groups of 8 controls
received olive oil.
(c) The effects of i.m. Cy A and variation in
the time of its administration were studied
using rat sarcoma MC24. Cy A was inoculated
i.m. into the non-tumour-bearing thighs of
groups of 8 rats at a dose of 40 mg/kg on 3
alternate days as follows: before tumour
implantation, at various times during tumour
growth, and after tumour resection. Similar
experiments were performed using single
inoculations of 80 mg/kg Cy A.
RESULTS
Growth rates of tumours
Fig. 1 shows the growth rates of mouse
sarcoma FS6 and rat sarcoma MC24 in
control and Cy A-treated animals. It can
be seen that daily doses of 20 or 80 mg/kg
of this agent had no significant effect on
either tumour; similar results were ob-
tained with the other tumours tested.
Also, tumours grown i.m. for metastasis
studies were regularly dissected and
weighed after excision; those from Cy A-
treated and control animals were found to
be of comparable mass, even when
counted numbers of tumour cells were
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FIG. 1. Growtlh of mouse sarcoma F86 an(d
rat sarcoma MC24 in Cy A-treated (*)
an(d control (-) animals.
inoculated (e.g. HSN.TC and L5178YE).
Thus, while measurement of tumour
diameter is a very crude parameter, these
results indicate that Cy A is probably not
directly toxic to tumour cells, and also
that alterations in metastatic patterns
cannot be ascribed simply to the presence
of larger tumours in treated groups.
Influence of Cyclosporin A on pattern.s of
spontaneous metastasis
Oral administration.-Fig. 2 shows the
patterns of spontaneous metastasis of
mouse sarcomas FS6 and FS29, and the
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FIm. 2. Effect of orally a(dministered Cy A
on metastasis of mouse sarcomas FS6 an(d
FS29. Ttumours iinoculate(d i.m. Day -110
andl excised on 1)ay 0. 111 (lays oni which
Cy A was given. Mletastases: O lulng;
O lymplh no(le(s); V kidineyv; 0 liver.
effects ofCy A. Both tumours are immuno-
genic and have relatively low rates of
metastasis, normally confined to the lungs,
but in both cases administration of Cy A
to tumour-bearing animals significantly
increased the incidence and, in the case of
FS6, the distribution of metastases. Cy A
had no detectable effects on the incidence
of metastases when given after tumour
excision, although 20% of animals de-
veloped lymphnode metastases fro;n F829
in addition to pulmonary metastases. It is
now known that Cy A is poorly absorbed
when given orally in suspension, but
nevertheless this regime was sufficient to
enhance metastasis of both tumours.
Subcutaneous administration. -Fig. 3
shows the effect of Cy A on the metastasis
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FIo. 3.-Effect of s.c. inoculation of Cy A on
metastasis of rat sarcomas MC24, MC26 and
HSN.TC. Tumours inoculated i.m. on Day
-14 and excised on Day 0. Symbols as in
Fig. 2.
TABLE I.-Effect of s.c. Cyclosporin A on
L5178YE metastasis
(A) L5178YE grown i.m., excised Day 10
Metastases
Controls Cy A-treated
Total incidence 1/10 10/10
Lymph node 1/10 10/10
Liver 0/10 10/10
Spleen 0/10 7/10
(B) L5178YE grown s.c. for 14 days
Total incidence
Liver
Spleen
Lymph node
Ovary
Metastases
Controls Cy A-treated
0/10 10/10
8/10
9/10
2/10
5/10
of 3 rat sarcomas. All are highly immuno-
genic, and although they grow readily in
immunocompetent animals and never re-
gress, spontaneous metastasis is rare. It is
clear from the diagram that administra-
tion of Cy A to tumour-bearing animals
has a dramatic effect on metastasis; the
incidence increased from 0% to 75% and
100% for MC26 and MC24 respectively,
and from 12.5% to 100% with HSN.TC.
If the same treatment schedule was de-
layed until after tumour excision, no
metastases developed from MC24 and
HSN.TC, and only 1/8 animals died with
pulmonary metastases from MC26 (not
shown).
Thus 2 mouse sarcomas and 3 rat
sarcomas all showed enhanced metastasis
when Cy A was administered either orally
or s.c. during tumour growth, but the
effect was not evident with either schedule
after "primary"-tumour excision.
Table I shows that the immunogenic T-
cell lymphoma L5178YE can also be in-
duced to metastasize in Cy A-treated
animals. Mice with either s.c. or i.m.
tumour grafts succumbed rapidly to wide-
spread disseminated disease, in contrast to
untreated animals which generally re-
mained tumour-free.
Fig. 4 shows the results when Cy A was
administered s.c. to mice bearing i.m.
squamous-cell carcinomas DM1, DM2 and
DM6, or mammary adenocarcinomas MT1,
(A) Tumours grown i.m. from 106 cells. 1 control
animal died 20 days after tumour excision with
single iliac lymphnode metastasis, all others are
alive and well at 100 days. All Cy A-treated anirmals
died between 4 and 7 days after excision, with
multiple metastases.
(B) Tumours grown s.c. from 106 cells. Animals
killed after 14 days of tumour growth and examined
for gross metastases (confirmed histologically). 2
animals had splenic metastases only, in all others
multiple sites were involved.
MT3 and MT5. Since the 3 tumours ofeach
type behaved similarly, the results have
been pooled. The CBA mammary carcin-
omas have negligible immunogenicity, and
the squamous carcinomas also have low
immunogenicity. TD50 values for MT
tumours in unimmunized CBA/Ca mice
were 2 x 104, 5 x 104 and 8 x 103 and these
were essentially unchanged in animals
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FIm. 4. Effect of s.c. inoculation of Cy A on
metastasis of mouse squamous-cell car-
cinomas DM1, DM2 and DM6 (data
pooled) and mouse mammary carcinomas
MT1, MT3 and MT5 (data pooled). Tumours
inoculated i.m. onDay -10 and excised on
Day 0. Symbols as in Fig. 2.
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immunized by excision ofgrowing tumours
2 weeks before challenge. In C57BL/Cbi
mice immunized by this means with the
3 squamous-cell carcinomas, the TD50 was
raised from between 5 x 102 and 5 x 103 to
between 5 x 103 and 105, an average of
1-1 Ilogs.
None ofthe 6 tumours grown in animals
treated with high doses of Cy A showed
enhanced metastasis (in terms ofincidence,
rate of appearance or distribution) in con-
trast to the results with the sarcomas and
lymphomas already described.
Intramuscular administration.-Fig. 5
shows the results obtained when 3 x 40
mg/kg i.m. injections of Cy A were given
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Fic- 5. Effect of i.m. inoculation of Cy A
(3 x 40 mg/kg) on metastasis of rat sarcoma
MC24. Tumours inoculated i.m. on Day -21
and excised on Day 0. Symbols as in Fig. 2.
on alternate days to rats with MC24
sarcoma. It can be seen that, irrespective
of the time of drug administration during
tumour growth, animals succumbed
rapidly to pulmonary and/or lymphatic
metastases, in contrast to control animals,
which were all tumour-free at 250 days.
Also, in this case, even ifCy A administra-
tion was delayed until 6-10 days after
tumour excision, 7/8 animals died before
Day 45, and all were dead by Day 195.
In a second experiment, animals re-
ceived only a single i.m. injection of80 mg/
kg of Cy A and Fig. 6 shows the results.
All control animals were free ofmetastases
on Day 200 after tumour excision, as were
those treated with Cy A 7 days before
tumour implantation. However, treatment
on Day -3 induced lymphnode meta-
stases in 2/4 animals, and all animals
receiving treatment on the same day as
the tumour inoculum died subsequently
with lymphatic and pulmonary meta-
stases.
I I
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FIG. 6. Effect of single (80 mg/kg) i.m.
inoculation of Cy A on metastasis of rat
sarcoma MC24. Tumours inoculated i.m.
and excised after 15 days. Key: C-
controls. Metastases:L lung; LN lymplh-
no(le(s).
Although the number of animals in the
groups was small, it is clear that even a
single injection of Cy A, whether early or
late during tumour development or up to
3-4 weeks after tumour excision, induced
a significant increase in metastases. It is
possible that the inoculation of Cy A in oil
gives rise to a "depot effect", so that the
drug is available for some time after its
administration. However, the reduced
effectiveness when the drug was ad-
ministered 3 days before the implant, and
the lack of effect when given on Day -7,
indicate that it probably persists systemic-
ally little longer than 3 days. It has been
shown also that animals receiving con-
tinuous daily doses of Cy A recovered
rapidly from the effects once treatment
was terminated (Denham et al., 1980).
These experiments indicate that Cy A can
inhibit established as well as developing
anti-tumour immunity, if the dose and
route of administration are suitable. This
effect is not confined to the MC24 sarcoma,
similar results having since been obtained
with other tumours (e.g. MC26, HSN, FS6,
L5178YE); and it has also been noted that
Cy A treatment ofimmunized animals can
reduce considerably their resistance to
subsequent tumour-cell challenge.
I i iq i~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~l i F
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Metastatic potential of Cy A-induced
metastases
When overt metastases appear in anii-
mals treated with Cy A, it can be assumed
that their development was "induced" by
the effects of Cv A if control animals re-
main tumour-free. This could be due to
augmentation of the number of cells
escaping from the primary tumour, or
their enhanced survival in the circulation
or at distant sites in the immunosup-
pressed host. When metastases develop in
animals treated after excision of primary
tumour implants, these must have arisen
from cells which had already dis-
seminated at the time of treatment, and
which would have remained "dormant" in
immunocompetent animals. Thus Cy A
treatment allows an investigation of the
properties of both "induced" and "dor-
mant" metastases (these being operational
TABLE II. Metastat
mary" tumours 6
Cy A-treated anima
Tu-monu irmplanlt
(A) Parent "1 " turnours
AMC24
AIC26
HSN.TC
FS6
151 78YE
(B) *"Indltieed' metastases
MNIC'24 lutng
AIC24 luing
AI\C24 lymph niode
AIC26 lung
lC26-hlung
HSN.TC lymp}l nocie
FS6-lung
1'86 liver
F'S6 kidnev
L5178Y-liver
1 78Y spleen
L5178Y lymph nio(le
(C) t"Dormant," metastases
AIC24 lutng
IC24 lymplh node
MC26 -lung
definitions) for tumours where the inci-
dence of overt spontaneous metastases is
negligible (e.g. MC24, MC26, HSN.TC,
L5178YE).
Table II shows the metastatic potential
of 5 "parent" tumours and 15 of their
"induced" or "dormant" metastases, de-
rived from experiments illustrated in
Figs 2, 3 and 5, and Table I. It is clear that
in no case did the metastases show signifi-
cantly enhanced propensities for dissemi-
nation and growth at secondary sites. Also,
when metastases did develop, they were
not necessarily confined to the site from
which they were derived, e.g. transplanted
lymphnode metastases yielded lung meta-
stases (MC24, HISN.TC) and kidneyyielded
lung metastases (FS6).
D)ISCUSSION
These results indicate that oral or
ic potential of "pri- parenteral Cy A treatment of both rats
and mice bearing immunogenic sarcomas ind metastases from . tn nd leads to a marked increase in the Ies subsequent development of metastases.
Mretastases Evidence that Cy A was exerting its effects
Jrwidcnwe Site~ via immunosuppression is as follows:
()/8
(1 8
1/8
2/10
1/10
(08
0/8
1/8
0/8
1/8
1/8
:3/1()
1/1()
()/I() 0/1(>
()/g
018
018
* Aetastases (leveloping after treatment
during the "primary" tumour growth.
t Metastases developing when treatm(
mals was after excision of 1 tumour.
L =lItng; LN =lymphl node.
(1) Doses similar to those used in this
study have been shown to permit the
L survival of skin allografts in our rat
LN LN colony (Denham et al., 1980).
(2) Production of specific antibody to
tumour antigens estimated by a direct
binding assay was totally inhibited, as l,N+L described previously in athymic animals
L (Eccles et al., 1979).
L (3) The host-cell infiltration of tumours L+ N was marliedly reduced; e.g. the frequency
L of mononuclear Fc receptor-positive
phagocytic cells in MC24 and MC26
sarcomas was 22-30°, in control animals,
but less than 3%o in Cy A-treated rats.
This effect is also found in athymic or
LN +L thymectomized/irradiated hosts (Eccles
et al., 1979; Eccles & Alexander, 1976).
ofanimals (4) No effects ofCy A on tumour growth
suggestive ofdirect cytotoxicity were seen,
ent Of ani- the tumours in both treated and control
groups being of comparable size.
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(5) The doses used were found to have
no effects on any parameters of blood
coagulability tested (Hilgard et al., to be
published).
The observations are consisteunt with
earlier work from many laboratories
showing that various forms of T-lympho-
cyte depletion/inhibition generallyenhance
spontaneous metastasis (reviewed by
Eccles, 1978). Treatment with high i.m.
doses of Cy A after excision of primary
sarcoma implants also induced metastases
in a high proportion of animals, by allow-
ing outgrowth of cells that had alreadv
disseminated at the time of treatment and
which would normally have been con-
trolled by the host. These data are con-
sistent with the idea that even "non-
metastatic" sarcomas release cells which
colonize secondary sites and retain their
ability to proliferate (Eccles & Alexander,
1975).
Similar results were obtained with the
immunogenic L5178YE lymphoma which
rarely yields metastases in normal animals
but which disseminated readily in Cy A-
treated mice. Although thisdrug isthought
to inhibit T-cell proliferation (White et al.,
1979a), and has been shown to interfere
with the in vitro growth of a T-cell like
lymphoma, but not a B-cell like lymphoma
(White et al., 1979b), no significant effects
were seen on the growth of the T-cell
lymphoma L5178YE in vivo. It is possible
that the drug did not reach the tumour
cells at concentrations adequate to exert
cytostatic effects, but the systemic effects
on the host were sufficient to allow the
tumour to escape from immunological
control.
The metastatic potential of induced and
"dormant" metastases was of interest,
since it has been suggested that meta-
stases develop from subpopulations ofcells
of unique metastasizing ability, pre-
existing within primary tumours (Poste &
Fidler, 1 980). It might be postulated,
therefore, that Cy A treatment had
allowed the metastatic potential of these
cells to be expressed, and that their in-
trinsic metastatic properties wtouldI persist
on transplantation into normal animals.
However, the data provide no evidence
that Cy A-indctued metastases wNvere de-
rived from metastatic variant clones with
specific-organ-colonizing abilities. Tflhese
results are similar to those reported for
spontaneouis metastases developing from
a wide varietry of tumnioturs in syngeneic
hosts (Eccles & Alexander, to be pub-
lished). Similarly, La-178YE andl its meta-
static subline L51 78YES, in spite of
apparently significant differences in in-
herent properties such as motility, ad-
hesion and invasiveness, behaveidentically
in immunosuppressed hosts, and it is now
evident that their in vivo behaviouir is
primarily determined by the host immune
environment (Davey et al., 1979). Thus it
is suggested thlat, for anaplastic tuimoturs in
which the population is inherently highly
clonogenic (i.e. capable of growing from
very low inocula in vivo) the ultimate sur-
vival of disseminated cells is determined
mainly by the degree of host immutnity
they invoke.
The failure of Cy A to affect the meta-
stasis of all 6 carcinomas tested is in direct
contrast to these resuilts. It is not sur-
prising that an immunosuippressive agent
should only potentiate metastases of im-
munogenic tumoturs, but what is ofinterest
is thfat the carcinom-as stuidied, unlike
poorly immunogenic sarcomias and lvmph-
omas (Eccles & Alexander, 1974; Dlavey
et al., 1979), had very low rates of spon-
taneous metastasis, and clearly their
failure to disseminate successfully was not
duie to T-cell-dependent host immtune
responses.
All the carcinomas in early transplanit
generations were moderately or well
differentiated and it is possible that a
significant component of the population
undergoes maturation, with concomiitant
loss of proliferative capacity. This is sug-
gested also by the fact that they are, as a
whole, much less clonogenic in vivo than
the sarcomas and lymphomas; high cell
numbers being required for growth (even
when injected i.v.) regardless of host
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immune status (Tarin & Price, 1979).
Inverse correlations between the degree of
differentiation ofanimal tumours and their
metastatic capacity have been reported
(Belnap et al., 1979; Sordat et al., 1977)
and we noticed also that with successive
in vivo passages certain tumours became
less well differentiated and this was always
associated with a decrease in TD50 values
and increased incidence of spontaneous
metastasis (unpublished observations).
Thus anaplastic non-immunogenic carcin-
omas can behave similarly totheir counter-
parts ofmesodermal origin.
These apparent correlations invite
speculation, but more work is required to
determine the actual proliferative capa-
city, growth fraction and other kinetic
parameters of tumour-cell populations of
different histological appearance in order
to explore these interesting possibilities.
It has been shown that maturation pro-
motors (e.g. dimethylformamide) can in-
duce tumour cells to develop a more
differentiated phenotype in vitro with
resulting loss of tumorigenicity in vivo
(Calabresi et al., 1979) and experiments are
in progress to determine whether similar
compounds might operate in vivo to re-
duce tumour growth and metastasis.
In summary, the use of Cy A as an
immunosuppressant with few side effects
has allowed a survey of the role of T-cell-
dependent immune responses in the con-
trol of metastases in a variety of systems.
It is evident that with some tumours
which are demonstrably immunogenic (as
in the sarcomas and lymphomas described)
T-cell function is required not only for the
initiation of an immune response, but also
for its maintenance, even after "primary"
tumour resection. For tumours of negli-
gible immunogenicity (e.g. the mammary
and squamous-cell carcinomas) inhibition
of T-cell function had no effect on meta-
stases, and in these cases factors other than
host immunity must be preventing suc-
cessful dissemination.
This work was supported by a programme grant
from The Medical Research Council and Cancer
Research Campaign. We are indebted to Sandoz
Ltd, Basle, for gifts ofCyclosporin A.
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